Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.33 |
| ▸ | USP14 | P54578 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13582483 | 0.90 | BACE1 (0.35) | BACE1KDM4EALDH1A1ALOX5GAA | |
| SCHEMBL6120098 | 0.87 | FFAR4 (0.34) | BACE1KDM4EALDH1A1ALOX5GAA | |
| SCHEMBL1751379 | 0.87 | FFAR1 (0.34) | BACE1KDM4EALDH1A1ALOX5GAA | |
| SCHEMBL5871550 | 0.85 | MEN1 (0.37) | BACE1 | |
| SCHEMBL29377445 | 0.83 | KCNH2 (0.33) | BACE1KDM4EALDH1A1ALOX5GAA | |
| SCHEMBL26978564 | 0.83 | KCNH2 (0.33) | BACE1KDM4EALDH1A1ALOX5GAA | |
| SCHEMBL2876790 | 0.82 | CA2 (0.45) | BACE1KDM4EALDH1A1ALOX5GAA | |
| SCHEMBL5871245 | 0.80 | CYP4F2 (0.43) | BACE1KDM4EALDH1A1ALOX5GAA | |
| SCHEMBL2236069 | 0.79 | RXRA (0.37) | BACE1CA2PPARAUSP14 | |
| SCHEMBL6156231 | 0.79 | MAOB (0.41) | BACE1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | BACE1 4259/4885KDM4E 927/4885ALDH1A1 3599/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | BACE1 3717/4885KDM4E 1127/4885ALDH1A1 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.